Deep Genomics, announced the closing of a $180 million Series C financing round. This round was led by SoftBank Vision Fund 2 with participation from new investors Canadian Pension Plan Investment Board (CPP Investments), Fidelity Management & Research Company LLC, Alexandria Venture Investments.
Existing investors Amplitude Ventures, Khosla Ventures, Magnetic Ventures, and True Ventures also participated in the funding round.
The Series C funds will help the company expand the AI Workbench and scale its pipeline to 30 programs.
Company: Deep Genomics Inc.
Raised: $180.0M
Round: Series C
Funding Month: July 2021
Lead Investors: SoftBank Vision Fund 2
Additional Investors: Canadian Pension Plan Investment Board (CPP Investments), Fidelity Management & Research Company LLC, Alexandria Venture Investments, Amplitude Ventures, Khosla Ventures, Magnetic Ventures, and True Ventures.
Company Website: http://www.deepgenomics.com/
Software Category: AI Workbench
About the Company: Deep Genomics uses artificial intelligence and machine learning to program and prioritize transformational RNA therapies for almost any gene in any genetic condition. The platform, called the AI Workbench, enables Deep Genomics to decode vast amounts of data on RNA biology, identify novel targets for genetically defined diseases, and produce therapeutic programs with a high success rate. Almost everyone will suffer from disease affected by genetics at some point in their life, and Deep Genomics aims to be there for them with a genetically precise therapy.
Source: https://www.deepgenomics.com/news/deep-genomics-raises-180m-series-c-financing/